Jordan Clark
Chief Data Officer | Data Solutions
As Chief Data Officer and Board Member, Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering, data science and AI, to deliver cutting-edge analytics to our clients and laboratories. With over a decade at Diaceutics, he has played a central role in scaling the business into a global recurring-revenue platform, overseeing 300+ diagnostic commercialization projects supporting top-20 pharma. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise, alongside his renowned proficiency in bioinformatics and biomarker testing honed through his involvement with UK NEQAS.
Connect
As Chief Data Officer and Board Member, Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering, data science and AI, to deliver cutting-edge analytics to our clients and laboratories. With over a decade at Diaceutics, he has played a central role in scaling the business into a global recurring-revenue platform, overseeing 300+ diagnostic commercialization projects supporting top-20 pharma. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise, alongside his renowned proficiency in bioinformatics and biomarker testing honed through his involvement with UK NEQAS.
Resources written by Jordan Clark:
From Blockbusters to Biomarkers: Rethinking Commercialization for the Precision Era and the Importance of Diagnostic Testing
Discover how Targeted Commercialization transforms precision medicine by aligning diagnostic testing with therapy launches, ensuring the right patients receive timely treatments.
Why Traditional HCP Engagement Models Are No Longer Fit for Purpose Spotlight
Scientific innovation has accelerated. But the commercial models used to engage HCPs have not kept pace. At Fierce Pharma Week 2026, we challenged traditional targeting models and explored how diagnostic intelligence can bring greater clinical context and precision to the moments when treatment decisions are taking shape.